Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 241
Filter
1.
ESMO Open ; 7(1): 100394, 2022 02.
Article in English | MEDLINE | ID: mdl-35158207

ABSTRACT

BACKGROUND: Nivolumab plus ipilimumab demonstrated clinically meaningful improvement in efficacy versus chemotherapy with a manageable safety profile in patients with advanced non-small cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% or <1% in Part 1 of CheckMate 227. Here we report efficacy and safety results for the Asian subpopulation. METHODS: Patients with stage IV/recurrent NSCLC were randomized 1 : 1 : 1 to nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy (PD-L1 ≥1%) or nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy (PD-L1 <1%). Overall survival (OS), progression-free survival, objective response rate, duration of response, and safety were evaluated among patients in Japan, South Korea, and Taiwan. RESULTS: In the Asian subpopulation with PD-L1 ≥1%, 81 patients received nivolumab plus ipilimumab and 81 received chemotherapy. Median OS was not reached with nivolumab plus ipilimumab versus 24.8 months with chemotherapy; 3-year OS rate was 53% versus 37% [hazard ratio (HR), 0.72; 95% confidence interval (CI) 0.47-1.11]. The 3-year progression-free survival rate was 26% versus 7% (HR, 0.65; 95% CI 0.45-0.96), objective response rate was 56% versus 37%, and median duration of response was 29.0 months (95% CI 15.0 months-not reached) versus 6.9 months (95% CI 3.9-11.1 months). Similar results were observed regardless of tumor PD-L1 expression and in Japanese patients. Grade 3-4 treatment-related adverse events occurred in 40% of patients receiving nivolumab plus ipilimumab and 36% receiving chemotherapy, in the overall Asian subpopulation (tumor PD-L1 expression ≥1% and <1%); no new safety signals were identified. CONCLUSIONS: At 3-year follow-up, nivolumab plus ipilimumab provided durable long-term efficacy benefits versus chemotherapy regardless of tumor PD-L1 expression in the Asian subpopulation, including Japanese patients. Consistent with findings for all randomized patients, these data support the use of nivolumab plus ipilimumab as first-line treatment of Asian patients with advanced NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Humans , Ipilimumab/pharmacology , Ipilimumab/therapeutic use , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Neoplasm Recurrence, Local/chemically induced , Neoplasm Recurrence, Local/drug therapy , Nivolumab/pharmacology , Nivolumab/therapeutic use
2.
J Laryngol Otol ; 135(2): 153-158, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33551000

ABSTRACT

BACKGROUND: Transoral robotic surgery is frequently described, driven by the desire to offer a less morbid alternative to chemoradiation. However, the objective evaluation of post-operative function has rarely been reported. Therefore, high-resolution manometry was used in this study to evaluate the impact of changes in peri-operative swallowing function on pharyngeal pressure events. METHODS: Ten patients with various stages of oropharyngeal cancer underwent transoral surgery. High-resolution manometry and videofluoroscopic swallow studies were performed before surgery and two months afterwards. The following parameters were obtained: velopharyngeal and mesopharyngeal post-deglutitive upper oesophageal sphincter pressures, velo-meso-hypopharyngeal contractile integral, upper oesophageal sphincter relaxation pressure, and pharyngeal velocity. RESULTS: There was no significant difference in pharyngeal pressure or contractile integral pre- versus post-operatively. However, pharyngeal velocity was significantly higher post-operatively than pre-operatively. CONCLUSION: High-resolution manometry showed that transoral surgery in patients without pre-operative dysphagia preserved pharyngeal constriction. However, transoral surgery might produce scar formation in the pharynx, which could lead to narrowing of the pharynx.


Subject(s)
Deglutition/physiology , Oropharyngeal Neoplasms/surgery , Pharynx/physiopathology , Robotic Surgical Procedures/adverse effects , Aged , Aged, 80 and over , Deglutition Disorders/physiopathology , Esophageal Sphincter, Upper/physiology , Female , Humans , Male , Manometry/methods , Middle Aged , Muscle Contraction/physiology , Neoplasm Staging , Oropharyngeal Neoplasms/pathology , Postoperative Period , Pressure , Robotic Surgical Procedures/methods , Squamous Cell Carcinoma of Head and Neck/epidemiology , Squamous Cell Carcinoma of Head and Neck/pathology , Squamous Cell Carcinoma of Head and Neck/surgery
3.
Radiat Prot Dosimetry ; 184(3-4): 518-522, 2019 Oct 01.
Article in English | MEDLINE | ID: mdl-31330027

ABSTRACT

Soil samples from the surface to a 5 cm depth were collected at a residential house in Koriyama City, Fukushima Prefecture using a scraper plate every three months from March 2014 to September 2014 to evaluate the vertical distribution profiles and inventories of 134Cs and 137Cs in soil. The vertical distribution profiles of radiocesium (134Cs and 137Cs) in soil showed that greater than 86% of the total radiocesium was absorbed in the upper 2 cm 3 years after the accident. Radiocesium in the surface layer seems to move to the lower layer over time. The migration of radiocesium in surface layer might be influenced by the ground surface runoff by rainfall. Radiocesium inventories in June increased significantly over the short period between March and June. In contrast, the radiocesium inventories in September did not increase significantly compared to the values in June. Radiocesium resuspension and deposition caused by decontamination work and meteorological events might be one possible reason for the increased radiocesium inventories observed in June.


Subject(s)
Cesium Radioisotopes/analysis , Fukushima Nuclear Accident , Radiation Exposure/analysis , Radiation Monitoring/methods , Soil Pollutants, Radioactive/analysis , Decontamination , Housing , Humans , Nuclear Power Plants
4.
Radiat Prot Dosimetry ; 184(3-4): 328-333, 2019 Oct 01.
Article in English | MEDLINE | ID: mdl-31038704

ABSTRACT

We have recently have developed an in-situ multiple-channel depth distribution spectrometer (DDS) that can easily acquire on-site measurements of the depth distribution of specific radioactivities of Cs-134 and Cs-137 underground. Despite considerable improvements in the hardware developed for this device, the quantitative method for determining of radioactivities with this DDS device cannot yet achieve satisfactory performance for practical use. For example, this method cannot discriminate each γ-ray spectra of Cs-134 and Cs-137 acquired by the 20 thallium-doped caesium iodine CsI(Tl) scintillation crystal detectors of the DDS device from corresponding depth levels of underground soil. Therefore, we have applied deep learning neural network (DLNN) as a novel radiation measurement technique to discriminate the spectra and to determine the specific radioactivities of Cs-134 and Cs-137. We have developed model soil layers on a virtual space in Monte-Carlo based PHITS simulations and transported γ-ray radiation generated from a particular single soil layer or multiple layers as radiation sources; next, we performed PHITS calculations of those specific radioactivity measurements for each soil layer using DDS device based on machine learning via the DLNN algorithm. In this study, we obtained informative results regarding the feasibility of the proposal innovative radiation measurement method for further practical use in on-site applications.


Subject(s)
Algorithms , Cesium Radioisotopes/analysis , Computer Simulation , Scintillation Counting/instrumentation , Soil Pollutants, Radioactive/analysis , Spectrometry, Gamma , Feasibility Studies , Humans , Radiation Monitoring
5.
Science ; 364(6437): 252, 2019 04 19.
Article in English | MEDLINE | ID: mdl-30890587

ABSTRACT

The near-Earth carbonaceous asteroid 162173 Ryugu is thought to have been produced from a parent body that contained water ice and organic molecules. The Hayabusa2 spacecraft has obtained global multicolor images of Ryugu. Geomorphological features present include a circum-equatorial ridge, east-west dichotomy, high boulder abundances across the entire surface, and impact craters. Age estimates from the craters indicate a resurfacing age of [Formula: see text] years for the top 1-meter layer. Ryugu is among the darkest known bodies in the Solar System. The high abundance and spectral properties of boulders are consistent with moderately dehydrated materials, analogous to thermally metamorphosed meteorites found on Earth. The general uniformity in color across Ryugu's surface supports partial dehydration due to internal heating of the asteroid's parent body.

6.
J Laryngol Otol ; 132(12): 1128-1133, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30674368

ABSTRACT

BACKGROUND: In endoscopic cricopharyngeal myotomy, surgeons sometimes have concerns about performing an adequate incision with only a narrow intra-cavital view from one direction. In order to overcome these issues, fluoroscopic radiography was used during endoscopic cricopharyngeal myotomy. METHODS: Peri-operative fluoroscopic radiography was utilised to check the position of the diverticuloscope, and to confirm the extent of the incision during surgery. A balloon catheter was used to determine whether the cricopharyngeal muscle was sufficiently resected. Blood loss, peri-operative complications, and functional oral swallowing scale and penetration aspiration scale scores were evaluated. RESULTS: In 12 out of 15 patients, intra-operative fluoroscopic radiography showed the diverticuloscope positioned in the post-cricoid area, and the cricopharyngeal muscle was raised and the surgery completed without adverse effect. Swallowing functions improved following surgery. CONCLUSION: Intra-operative fluoroscopy might improve endoscopic cricopharyngeal myotomy by allowing surgeons to confirm the extent of resection, and by reducing peri-operative morbidity and complication rates.


Subject(s)
Deglutition Disorders/surgery , Endoscopy/methods , Myotomy/methods , Pharyngeal Muscles/surgery , Radiography, Interventional/methods , Aged , Deglutition , Deglutition Disorders/etiology , Endoscopy/adverse effects , Female , Fluoroscopy/methods , Humans , Male , Middle Aged , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Treatment Outcome
7.
Ann Oncol ; 28(1): 136-141, 2017 01 01.
Article in English | MEDLINE | ID: mdl-28177428

ABSTRACT

Background: Analysis of circulating cell-free DNA (cfDNA) is under intensive investigation for its potential to identify tumor somatic mutations. We have now explored the usefulness of such liquid biopsy testing with both the digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS) during treatment of patients with the epidermal growth factor receptor (EGFR) inhibitor afatinib. Patients and methods: Eligible patients had advanced lung adenocarcinoma with EGFR activating mutations and were treated with afatinib. Plasma samples were collected before and during (4 and 24 weeks) afatinib treatment as well as at disease progression. Tumor and plasma DNA were analyzed by dPCR and NGS. Results: Thirty-five patients were enrolled. The objective response rate and median progression-free survival (PFS) were 77.1% and 13.8 months, respectively. Tumor and plasma DNA were available for 32 patients. dPCR and NGS detected EGFR activating mutations in 81.3% and 71.9% of baseline cfDNA samples, respectively. In 19 patients treated with afatinib for ≥24 weeks, the number of EGFR mutant alleles detected in cfDNA by dPCR declined rapidly and markedly after treatment onset, becoming undetectable or detectable at only a low copy number (<10 copies per milliliter) at 4 weeks. Median PFS was slightly longer for patients with undetectable EGFR mutant alleles in cfDNA at 4 weeks than for those in whom such alleles were detectable (14.3 versus 10.0 months). A total of 45 somatic mutations was identified in baseline tumor DNA, and 30 (66.7%) of these mutations were identified in cfDNA by NGS. Allele frequency for somatic mutations in cfDNA determined by NGS changed concordantly during afatinib treatment with the number of EGFR mutant alleles determined by dPCR. Conclusions: Monitoring of cfDNA by dPCR is informative for prediction of afatinib efficacy, whereas that by NGS is reliable and has the potential to identify mechanisms of treatment resistance.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/genetics , Circulating Tumor DNA/genetics , ErbB Receptors/genetics , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Mutation , Quinazolines/therapeutic use , Adenocarcinoma/blood , Adenocarcinoma/enzymology , Adenocarcinoma of Lung , Afatinib , Circulating Tumor DNA/blood , ErbB Receptors/metabolism , Female , High-Throughput Nucleotide Sequencing/methods , Humans , Liquid Biopsy , Lung Neoplasms/blood , Lung Neoplasms/enzymology , Male , Neoplasm Staging , Polymerase Chain Reaction/methods , Prospective Studies , Quinazolines/adverse effects
8.
Gene Ther ; 23(6): 479-88, 2016 06.
Article in English | MEDLINE | ID: mdl-26905369

ABSTRACT

Oncolytic herpes simplex virus (HSV) vectors have attracted increasing attention as novel anti-cancer agents. HSV entry is triggered by the binding of glycoprotein D (gD) to its receptors, such as herpesvirus entry mediator or nectin-1. We have recently reported the construction of a fully retargeted HSV platform that incorporates single-chain antibodies (scFv) into gD to mediate entry exclusively via tumor-associated antigens. In this study, we created an scFv directed against epithelial cell adhesion molecule (EpCAM), a recognized carcinoma-associated antigen, and inserted it into the retargeted HSV platform that is ablated for gD recognition of its canonical receptors and contains the entry-enhancing mutations in gB we previously identified. We observed that both initial entry and subsequent cell-to-cell spread of the retargeted virus were stringently dependent on cellular EpCAM expression. Interestingly, the retargeted virus developed larger plaques on some of the human tumor lines tested than the control virus bearing wild-type gD. Intratumoral injection of the retargeted virus revealed antitumor activity in a mouse xenograft model. These observations illustrate the versatility of our retargeted HSV platform as it allows expansion of the oncolytic virus toolbox for the treatment of diverse cancers.


Subject(s)
Epithelial Cell Adhesion Molecule/genetics , Genetic Vectors/genetics , Herpesvirus 1, Human/genetics , Neoplasms/therapy , Neoplasms/virology , Oncolytic Virotherapy/methods , Animals , CHO Cells , Cell Adhesion Molecules/genetics , Cell Adhesion Molecules/metabolism , Cell Line, Tumor , Chlorocebus aethiops/immunology , Cricetulus , Epithelial Cell Adhesion Molecule/immunology , Female , Genetic Vectors/metabolism , Hep G2 Cells , Herpesvirus 1, Human/metabolism , Humans , Mice , Nectins , Random Allocation , Receptors, Virus/metabolism , Single-Chain Antibodies/genetics , Single-Chain Antibodies/immunology , Transfection/methods , Vero Cells , Viral Envelope Proteins/genetics , Viral Envelope Proteins/metabolism , Virus Internalization , Xenograft Model Antitumor Assays
9.
Radiat Prot Dosimetry ; 167(1-3): 358-64, 2015 Nov.
Article in English | MEDLINE | ID: mdl-25982790

ABSTRACT

Activities were introduced in Kashiwa city in the Tokyo metropolitan area to correspond to the elevated environmental radiation level after the disaster of the Fukushima Daiichi nuclear power plant. These were based on a strong cooperation between local governments and experts. Ambient dose rate and radioactivity of foodstuff produced inside of the city have been monitored. Representative ambient dose rates around living environments have almost already become their original levels of the pre-accident because of the decontamination activity, natural washout and effective half-lives of radioactivity. The internal annual dose due to radioactive cesium under the policy of 'Local Production for Local Consumption' is estimated as extremely low comparing the variation range due to natural radioactivity. Systematic survey around a retention basin has been started. All of these latest monitoring data would be one of the core information for the policy making as well as a cost-benefit discussion and risk communication.


Subject(s)
Cooperative Behavior , Food Contamination, Radioactive/analysis , Fukushima Nuclear Accident , Local Government , Radiation Protection/methods , Radioactive Fallout/analysis , Decontamination/methods , Expert Testimony/methods , Food Contamination, Radioactive/prevention & control , Interinstitutional Relations , Radioactive Fallout/prevention & control , Safety Management/organization & administration
10.
Transplant Proc ; 47(3): 809-14, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25891736

ABSTRACT

We previously reported our data on telaprevir (TVR) used in combination with pegylated-interferon and ribavirin (PEG-IFN/RBV) for the treatment of recurrent hepatitis C virus (HCV) genotype 1 infection after liver transplantation (LT). TVR substantially increases the blood levels of immunosuppressive agents such as cyclosporine and tacrolimus for drug-drug interactions. On the other hand, the effect of simeprevir (SMV) on the blood levels of these immunosuppressive agents is unclear. We report 2 patients who achieved viral responses with little effect on the blood levels of cyclosporine and tacrolimus using SMV plus PEG-IFN/RBV treatment. The first was a 71-year-old woman with HCV-related liver cirrhosis and hepatocellular carcinoma who failed to respond to PEG-IFN/RBV after living donor LT. She was treated with 40 mg/d of cyclosporine, and received SMV plus PEG-IFN/RBV treatment. The second was a 65-year-old man with HCV-related liver cirrhosis who failed to respond to PEG-IFN/RBV after living donor LT. He was treated with 3 mg/d of tacrolimus, and received SMV plus PEG-IFN/RBV treatment. Serum HCV RNA became undetectable using TaqMan polymerase chain reaction (PCR) test after 4 weeks of treatment in both patients, and no remarkable fluctuation in blood concentration was observed either in cyclosporine or tacrolimus during the 12 weeks of SMV treatment. Completion of 12-week SMV triple therapy was followed by PEG-IFNα2b plus RBV, and both patients achieved sustained virological response 12 weeks after the end of treatment. SMV plus PEG-IFNRBV treatment showed a remarkable viral response with little effect on blood levels of immunosuppressive agents for recurrent HCV genotype 1 infection after LT.


Subject(s)
Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Protease Inhibitors/therapeutic use , Ribavirin/therapeutic use , Simeprevir/therapeutic use , Aged , Antiviral Agents/therapeutic use , Cyclosporine/blood , Drug Therapy, Combination , Female , Humans , Immunosuppressive Agents/therapeutic use , Interferon alpha-2 , Liver Cirrhosis/virology , Liver Transplantation , Living Donors , Male , Recombinant Proteins/therapeutic use , Tacrolimus/blood , Treatment Outcome
11.
Science ; 347(6229): 1455-8, 2015 Mar 27.
Article in English | MEDLINE | ID: mdl-25814579

ABSTRACT

Dominating finite-range interactions in many-body systems can lead to intriguing self-ordered phases of matter. For quantum magnets, Ising models with power-law interactions are among the most elementary systems that support such phases. These models can be implemented by laser coupling ensembles of ultracold atoms to Rydberg states. Here, we report on the experimental preparation of crystalline ground states of such spin systems. We observe a magnetization staircase as a function of the system size and show directly the emergence of crystalline states with vanishing susceptibility. Our results demonstrate the precise control of Rydberg many-body systems and may enable future studies of phase transitions and quantum correlations in interacting quantum magnets.

12.
J Viral Hepat ; 21(6): 397-404, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24750545

ABSTRACT

The standard therapy against hepatitis C virus (HCV) recurrence postliver transplantation includes interferon (IFN)α and ribavirin. IFNL4 ss469415590 polymorphism has been reported as a novel predictor of the response to IFN therapy for chronic HCV infection. We examined the impact of IFNL4 polymorphism on the responsiveness to IFN therapy after liver transplantation. Tissue specimens were collected from 80 HCV-infected recipients and 78 liver donors, and their IFNL4 ss469415590 genotype, hepatic IFNL4 and interferon-stimulated genes' mRNA expression levels were examined. The association of the polymorphism and expression levels in terms of the IFN therapy response to HCV recurrence was analysed. Most individuals who had rs8099917 risk alleles also had ss469415590 risk alleles (R(2) = 0.9). Sustained virological response (SVR) rates were higher in both liver graft recipients and transplants with ss469415590 TT/TT alleles than in those with the risk ΔG allele (P = 0.003 and P = 0.005, respectively). In recipients with ss469415590 TT/TT, IFNL4 TT mRNA levels showed no significant differences between livers of patients who responded to therapy and those who did not (P = 0.4). In recipients with the risk ΔG allele, IFNL4 ΔG mRNA expression levels were significantly lower in SVR patients than in non-SVR patients (P = 0.02). Hepatic interferon stimulable genes and IFNL4 mRNA expression were correlated. Our findings suggest that analysing the ss469415590 genotype and IFNL4 ΔG expression provides a novel prediction strategy for the possible response to IFN therapy after liver transplantation.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , Interleukins/genetics , Liver Transplantation , Polyethylene Glycols/therapeutic use , Polymorphism, Genetic , Transplant Recipients , Adult , Aged , Female , Gene Expression Profiling , Genotype , Hepatitis C/genetics , Humans , Interferon alpha-2 , Living Donors , Male , Middle Aged , Polymorphism, Single Nucleotide , Recombinant Proteins/therapeutic use , Recurrence , Ribavirin/therapeutic use , Treatment Outcome , Young Adult
13.
Bone Marrow Transplant ; 49(2): 254-7, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24037021

ABSTRACT

Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease of severe hyperinflammation caused by uncontrolled proliferation of activated lymphocytes and macrophages that secrete high amounts of inflammatory cytokines. HLH occurring after SCT is difficult to diagnose. It is characterized by severe clinical manifestations and high mortality. Despite current therapeutic approaches, outcomes remain poor. We analyzed the incidence and risk factors of HLH after SCT and the response to treatment and prognosis of 554 patients with HLH after SCT. The cumulative incidence of HLH after SCT was 4.3% (24/554). Use of etoposide in the conditioning regimen was only factor that reduced HLH after SCT (P=0.027). All patients who received autologous transplantation were successfully treated. Patients with liver dysfunction (for example, high total bilirubin level, prolonged prothrombin time and high level of fibrinogen degradation products) had a poor response to treatment for HLH. Physicians should be cautious of HLH, while not using etoposide for conditioning regimen.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Etoposide/therapeutic use , Lymphohistiocytosis, Hemophagocytic/drug therapy , Stem Cell Transplantation/adverse effects , Adolescent , Adult , Antineoplastic Agents, Phytogenic/administration & dosage , Child , Child, Preschool , Etoposide/administration & dosage , Female , Humans , Lymphohistiocytosis, Hemophagocytic/etiology , Male , Middle Aged , Risk Factors , Stem Cell Transplantation/methods , Young Adult
14.
Science ; 334(6053): 200-3, 2011 Oct 14.
Article in English | MEDLINE | ID: mdl-21998381

ABSTRACT

Quantum phases of matter are characterized by the underlying correlations of the many-body system. Although this is typically captured by a local order parameter, it has been shown that a broad class of many-body systems possesses a hidden nonlocal order. In the case of bosonic Mott insulators, the ground state properties are governed by quantum fluctuations in the form of correlated particle-hole pairs that lead to the emergence of a nonlocal string order in one dimension. By using high-resolution imaging of low-dimensional quantum gases in an optical lattice, we directly detect these pairs with single-site and single-particle sensitivity and observe string order in the one-dimensional case.

15.
Am J Transplant ; 11(6): 1325-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21645259

ABSTRACT

IL28B genetic polymorphism is related to interferon-sensitivity in chronic hepatitis C, but the significance of grafts carrying different genotypes from recipients is still unclear in liver transplantation. A 51-year-old Japanese male carrying a minor genotype underwent dual liver transplantation for liver cirrhosis due to hepatitis C virus (HCV). The left lobe graft carried a major genotype, and the right a minor genotype. He achieved virological response during the course of pegylated-interferon and ribavirin therapy against recurrent hepatitis C for 2 years, but HCV relapsed immediately at the end of the therapy. Two years after antiviral therapy, liver biopsy was performed from each graft. The specimens showed A1F0 in the left lobe graft and A2F2 in the right. Moreover, quantitative polymerase chain reaction was performed using RNA extracted from each specimen to see there was no HCV RNA in the left lobe whereas there was in the right. This case provides clear evidence that IL28B genetic variants determine interferon sensitivity in recurrent hepatitis C following liver transplantation, which could result in new strategies for donor selection or for posttransplant antiviral therapy to HCV positive recipients.


Subject(s)
Genetic Variation , Hepatitis C/genetics , Interleukins/genetics , Liver Transplantation/adverse effects , Base Sequence , DNA Primers , Humans , Interferons , Male , Middle Aged , Recurrence , Reverse Transcriptase Polymerase Chain Reaction
16.
Article in English | WPRIM (Western Pacific) | ID: wpr-975239

ABSTRACT

Purpose: The purpose of this study was to determine the relationship between the flexibility of the quadriceps femoris and the period from onset of the Osgood-Schlatter disease. Subjects: 45 patients (66 lower limbs) with Osgood-Schlatter disease participated in this study. Methods: Subjects were classified into acute-phase group (pain occurred within one month, 23 subjects, 32 lower limbs) and chronic-phase group (pain occurred over one month, 22 subjects, 34 lower limbs). As a measure of muscle flexibility of the quadriceps femoris, Heel-Buttock distance (HBD) were measured in all participants. Results: The flexibility of the quadriceps femoris within the chronic-phase group was significantly reduced flexibility (10.2 ± 6.5 cm) than in acute-phase group (4.6 ± 5.9 cm; p < 0.001). Conclusion: Patients of the OSD, even if not found a decrease in muscle flexibility of the quadriceps femoris during the acute phase, may be decrease the flexibility as time passes. Prevent the worse symptoms of OSD, it would be effective to introduce stretching from acute phase irrespective reduced flexibility in the physical therapy treatment plan.

17.
Transplant Proc ; 42(9): 3624-9, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21094828

ABSTRACT

INTRODUCTION: The optimal surgical technique has not been elucidated that reduces the occurrence of biliary strictures after living donor liver transplantation (LDLT). METHOD: We performed retrospective analysis of 193 consecutive LDLTs, including 78 right and 115 left lobe grafts. An external biliary stent was used for all of the cases. RESULTS: The overall 1-, 3-, and 5-year biliary stricture-free survival rates were 87.5%, 85.3%, and 85.3%, respectively. The 1- and 3-year biliary stricture-free survival rates for duct-to-duct reconstruction were 86.9% and 84.9%, and those for hepaticojejunostomy were 90.1% and 80.8%, respectively. A multivariate analysis revealed that the original number of graft bile ducts greater than the number of external stents, right lobe grafts, bile leaks, and recipient age older than 60 years represented the significant risk factors (P < .05) to develop a biliary stricture after LDLT. All cases with biliary strictures (n = 61) were initially managed nonsurgically, but 4 patients ultimately required interventions. CONCLUSIONS: Biliary reconstruction in LDLT using an appropriate number of external stents resulted in fairly acceptable outcomes. However, not only the proper use of stents or graft selection, but also nonsurgical factors, are important factors that determine the incidence of biliary strictures after LDLT.


Subject(s)
Cholestasis/prevention & control , Liver Transplantation/methods , Adolescent , Adult , Aged , Anastomosis, Surgical , Chi-Square Distribution , Child , Child, Preschool , Cholestasis/etiology , Constriction, Pathologic , Disease-Free Survival , Female , Humans , Infant , Infant, Newborn , Japan , Kaplan-Meier Estimate , Liver Transplantation/adverse effects , Liver Transplantation/instrumentation , Male , Middle Aged , Proportional Hazards Models , Retrospective Studies , Risk Assessment , Risk Factors , Stents , Time Factors , Young Adult
18.
Ann Oncol ; 21(4): 800-803, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19825887

ABSTRACT

BACKGROUND: Amrubicin, a new anthracycline agent, has shown high activity for small-cell lung cancer (SCLC) in previous studies. However, a combination regimen with amrubicin and platinum has been investigated little. On the basis of previous phase I study, we conducted this study to evaluate the efficacy and the safety of amrubicin and carboplatin for elderly patients with SCLC. METHODS: Chemotherapy-naive elderly patients with SCLC received amrubicin (35 mg/m(2), days 1-3) and carboplatin [area under the curve (AUC) 4.0, day1] every 3 weeks. The primary end point was overall response rate (ORR), and secondary end points were progression-free survival (PFS), overall survival and toxicity profile. RESULTS: From January 2005 to November 2007, 36 patients were enrolled [median age 76 (range 70-83); ECOG performance status of zero and one in 17 and 19 patients, respectively]. One complete response and 31 partial responses were observed (ORR 89%). Median PFS was 5.8 months and median survival time was 18.6 months. Grade 3-4 neutropenia was observed in 97% of the patients and six patients (17%) suffered from grade 3-4 febrile neutropenia. Other toxic effects were moderate and treatment-related death was not observed. CONCLUSIONS: Amrubicin combined with carboplatin is quite effective for SCLC with acceptable toxic effects even for the elderly population. Further evaluation of this regimen is warranted.


Subject(s)
Aged , Anthracyclines/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/administration & dosage , Lung Neoplasms/drug therapy , Small Cell Lung Carcinoma/drug therapy , Aged, 80 and over , Anthracyclines/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carboplatin/adverse effects , Female , Humans , Japan , Lung Neoplasms/mortality , Male , Small Cell Lung Carcinoma/mortality , Societies, Medical , Survival Analysis , Treatment Outcome
19.
Transplant Proc ; 41(10): 4246-52, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20005378

ABSTRACT

UNLABELLED: Although it has been recognized that interferon (IFN) treatment is crucial for recurrent hepatitis C after liver transplantation, its benefits have not been determined among patients without a sustained viral response (SVR). METHODS: Eighty patients who received IFN plus ribavirin treatment after living donor liver transplantation were grouped as follows: group I (n = 18) SVR; group II (n = 25) no-SVR but viral response [VR] positive; Group III (n = 13) no-VR but biochemical response [BR] positive; and group IV (n = 24) no-VR and no-BR. RESULTS: In groups II and III, not only the histological activity grade and fibrosis stage, but also the serum parameters including transaminases and type IV collagen were stable for 3 years after induction of IFN-based treatment. In group I, the activity grade and fibrosis stage significantly improved (P < .01). In group IV, the fibrosis stage significantly deteriorated (P < .01); the serum transaminases and type IV collagen were significantly higher than the other groups (P < .01). The mean duration of IFN treatment was significantly longer among group II (96 weeks) compared with the other cohorts (P < .05). The 5-year graft survival rate in groups II (91%) and III (100%) were comparable to those of group I (100%); group IV (62%) was significantly lower than the other groups (P < .05). CONCLUSION: IFN treatment was beneficial even among subjects with IFN-dependent VR or BR, although they did not achieve SVR.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/surgery , Interferon-alpha/therapeutic use , Liver Transplantation/physiology , Ribavirin/therapeutic use , Aged , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Female , Genotype , Graft Survival , Hepatitis C, Chronic/genetics , Hepatitis C, Chronic/pathology , Humans , Interferon alpha-2 , Liver Transplantation/mortality , Liver Transplantation/pathology , Living Donors , Male , Middle Aged , Polymerase Chain Reaction , RNA, Viral/blood , RNA, Viral/genetics , Recombinant Proteins , Recurrence , Retrospective Studies , Survival Rate
20.
Transplant Proc ; 41(5): 1976-8, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19545772

ABSTRACT

Portopulmonary hypertension (PPHTN) is a relatively rare complication of end-stage liver disease, and a serious problem in the context of liver transplantation. Herein we have reported a case of decompensated liver cirrhosis with PPHTN, which rapidly resolved after adult-to-adult living donor liver transplantation (LDLT). A 54-year-old man was referred to our hospital with end-stage liver cirrhosis owing to chronic hepatitis C. Preoperative mean pulmonary artery pressure (mPAP), as assessed by right heart catheterization, was 38 mm Hg. Continuous infusion of epoprostenol decreased the mPAP to 24 mm Hg over 44 days. He underwent LDLT using a right hepatic lobe graft donated by his son. The postoperative course was uneventful, epoprostenol was weaned by postoperative day (POD) 21, and the mPAP normalized to 21 mm Hg on POD 28. The patient was discharged on POD 31 without any vasodilators. Our case revealed that liver transplantation can rapidly resolve PPTHN.


Subject(s)
Hepatitis C, Chronic/surgery , Hypertension, Portal/etiology , Hypertension, Pulmonary/etiology , Liver Cirrhosis/surgery , Liver Transplantation/adverse effects , Antihypertensive Agents/therapeutic use , Epoprostenol/therapeutic use , Hemodynamics , Humans , Hypertension, Portal/drug therapy , Hypertension, Pulmonary/drug therapy , Liver Cirrhosis/complications , Living Donors , Male , Middle Aged , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...